Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial: Cambridge, UK Wednesday, April 2, 2025, 11:00 ...
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...
AZD0780 30mg taken daily demonstrated robust, dose-dependent, placebo-adjusted reductions in LDL-C from baseline to week 12 ...
The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
Zacks Investment Research on MSN2d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer IndicationAstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density ...
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback